Dr. David Williams, Ontario's Chief Medical Officer of Health announced the province's first confirmed case of vaccine-induced immune thrombotic thrombocytopenia or blood clot in a patient after receiving the AstraZeneca/COVISHIELD vaccine on Friday.
NACI initially recommended suspending the use of the Oxford-AstraZeneca vaccine on anyone younger than 55 as health authorities launched an investigation into reports of rare blood clots. "Additional details will not be publicly released to protect the patient's privacy".
Health Canada has approved the vaccine for all adults and several provinces have lowered the age limits to people aged 40 and older.More news: Russia: Doctors denied access to ‘very weak’ Alexei Navalny
Dr. Williams says this marks the fourth case out of more than 1.1 million doses of the AstraZeneca vaccine that have been administered in Canada to date.
Ontario will continue to offer the AstraZeneca vaccine to those 40 and up at the time of vaccination. "While these serious reactions remain extremely rare, we have a robust process in place to monitor for any adverse events and have taken steps to ensure that these events are identified and treated as quickly as possible", Williams said.
"At this time, and based on current evidence, NACI recommends that the AstraZeneca COVID-19 vaccine may be offered to individuals 30 years of age and older, without contraindications, if the individual does not wish to wait for an mRNA vaccine, and the benefits outweigh the risks", said Dr. Shelley Deeks, NACI vice-chair.More news: DOJ To Investigate Minneapolis Police For Possible Patterns Of Excessive Force
Quebec set a record for the second-straight day for COVID-19 vaccinations on Thursday, but deaths due to the virus continue to climb.
"On the basis of this ongoing review, the advice remains that the benefits of the vaccine outweigh the risks in the majority of people", the MHRA said.More news: Minneapolis ex-policeman Chauvin convicted of murder in Floyd case